{"id":191096,"date":"2024-06-12T12:26:04","date_gmt":"2024-06-12T17:26:04","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/06\/some-breast-cancer-treatments-linked-to-long-term-cardiovascular-disease-risk"},"modified":"2024-06-12T12:26:04","modified_gmt":"2024-06-12T17:26:04","slug":"some-breast-cancer-treatments-linked-to-long-term-cardiovascular-disease-risk","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/06\/some-breast-cancer-treatments-linked-to-long-term-cardiovascular-disease-risk","title":{"rendered":"Some Breast Cancer Treatments Linked to Long-term Cardiovascular Disease Risk"},"content":{"rendered":"

<\/a><\/p>\n

Some breast cancer survivors are at higher risk for cardiovascular disease following certain treatments. A new study is one of the first to provide evidence that may inform long-term and age-specific monitoring for these adverse outcomes. Researchers observed that breast cancer survivors treated with anthracyclines, a type of chemotherapy, and\/or trastuzumab, a targeted cancer therapy, had an increased long-term risk of cardiovascular disease, specifically cardiomyopathy\/heart failure, compared to women who did not receive chemotherapy. This study was published in the Journal of the National Cancer Institute<\/i> on May 8, 2024, and was selected for the journal\u2019s Early Career Investigator Research Section<\/a>.<\/p>\n

It is well established that certain breast cancer treatments, such as anthracycline and trastuzumab, can lead to heart damage, which contributes to a higher risk of cardiovascular disease later in life. However, current guidelines only recommend short-term cardiovascular surveillance up to two years after anthracycline and trastuzumab treatment because of a lack of evidence regarding long-term risks. Jacqueline B. Vo, Ph.D., R.N., M.P.H.<\/a>, assistant clinical investigator in the Radiation Epidemiology Branch (REB), led a team of researchers from REB, the Integrative Tumor Epidemiology Branch, the National Heart, Lung, and Blood Institute, and Kaiser Permanente, to explore whether patients could benefit from long-term surveillance. Their analysis included over 10,000 breast cancer survivors in the NCI-Kaiser Permanente Breast Cancer Survivors Cohort<\/a> with up to 24 years of follow up.<\/p>\n

They found that breast cancer survivors, especially those diagnosed at younger ages, had higher risks of cardiovascular disease and could benefit from long-term cardiovascular follow-up. Specifically, risk of cardiomyopathy\/heart failure were highest 10+ years after breast cancer diagnosis. Women who were diagnosed prior to age 55 had the highest risks for cardiomyopathy\/heart failure, which was nearly three times higher compared to women the same age who did not receive chemotherapy. One reason for the higher risk of cardiomyopathy\/heart failure among women diagnosed with breast cancer at younger ages is that this group is more likely to be diagnosed with more aggressive and\/or advanced tumors, which are more likely to be treated with anthracyclines and at higher doses. These results highlight the importance of extending current treatment-specific clinical guidelines for cardiovascular surveillance to include longer follow-up and focus on high-risk patients such as younger women.<\/p>\n","protected":false},"excerpt":{"rendered":"

Some breast cancer survivors are at higher risk for cardiovascular disease following certain treatments. A new study is one of the first to provide evidence that may inform long-term and age-specific monitoring for these adverse outcomes. Researchers observed that breast cancer survivors treated with anthracyclines, a type of chemotherapy, and\/or trastuzumab, a targeted cancer therapy, [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-191096","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/191096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=191096"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/191096\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=191096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=191096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=191096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}